Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT).
cardiac electronic implantable device
infection
microbiology
prevention
prophylaxis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
17
02
2021
accepted:
12
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
12
2021
Statut:
epublish
Résumé
The Prevention of Arrhythmia Device Infection Trial (PADIT) investigated whether intensification of perioperative prophylaxis could prevent cardiac implantable electronic device (CIED) infections. Compared with a single dose of cefazolin, the perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin did not significantly decrease the risk of infection. Our objective was to compare the microbiology of infections between study arms in PADIT. This was a post hoc analysis. Differences between study arms in the microbiology of infections were assessed at the level of individual patients and at the level of microorganisms using the Fisher exact test. Overall, 209 microorganisms were reported from 177 patients. The most common microorganisms were coagulase-negative staphylococci (CoNS; 82/209 [39.2%]) and Intensification of the prophylaxis led to significant changes in the microbiology of infections, despite the absence of a decrease in the overall risk of infections. These findings provide important insight on the physiopathology of CIED infections. NCT01002911.
Sections du résumé
BACKGROUND
BACKGROUND
The Prevention of Arrhythmia Device Infection Trial (PADIT) investigated whether intensification of perioperative prophylaxis could prevent cardiac implantable electronic device (CIED) infections. Compared with a single dose of cefazolin, the perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin did not significantly decrease the risk of infection. Our objective was to compare the microbiology of infections between study arms in PADIT.
METHODS
METHODS
This was a post hoc analysis. Differences between study arms in the microbiology of infections were assessed at the level of individual patients and at the level of microorganisms using the Fisher exact test.
RESULTS
RESULTS
Overall, 209 microorganisms were reported from 177 patients. The most common microorganisms were coagulase-negative staphylococci (CoNS; 82/209 [39.2%]) and
CONCLUSIONS
CONCLUSIONS
Intensification of the prophylaxis led to significant changes in the microbiology of infections, despite the absence of a decrease in the overall risk of infections. These findings provide important insight on the physiopathology of CIED infections.
TRIAL REGISTRATION
BACKGROUND
NCT01002911.
Identifiants
pubmed: 34859113
doi: 10.1093/ofid/ofab513
pii: ofab513
pmc: PMC8632784
doi:
Banques de données
ClinicalTrials.gov
['NCT01002911']
Types de publication
Journal Article
Langues
eng
Pagination
ofab513Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Heart Rhythm. 2010 Aug;7(8):1043-7
pubmed: 20470904
Infect Dis Clin North Am. 2018 Dec;32(4):811-825
pubmed: 30241711
Europace. 2016 Apr;18(4):473-8
pubmed: 26516219
J Am Coll Cardiol. 2018 Dec 18;72(24):3110-3111
pubmed: 30545449
J Am Coll Cardiol. 2019 Dec 10;74(23):2845-2854
pubmed: 31806127
Circulation. 2014 Sep 23;130(13):1037-43
pubmed: 25081281
Can J Cardiol. 2013 Jun;29(6):652-8
pubmed: 23702356
Curr Cardiol Rep. 2016 Jun;18(6):58
pubmed: 27147510
Infect Control Hosp Epidemiol. 2018 Sep;39(9):1030-1036
pubmed: 30226128
Eur Heart J. 2019 Jun 14;40(23):1862-1869
pubmed: 31155647
Antimicrob Agents Chemother. 1988 Feb;32(2):202-8
pubmed: 2966607
Am J Cardiovasc Dis. 2012;2(2):116-22
pubmed: 22720201
J Antimicrob Chemother. 2015 Feb;70(2):325-59
pubmed: 25355810
JACC Clin Electrophysiol. 2016 Aug;2(4):498-505
pubmed: 29759872
Circulation. 1998 May 12;97(18):1791-5
pubmed: 9603533
J Thorac Cardiovasc Surg. 2008 Dec;136(6):1522-7
pubmed: 19114201
J Cardiovasc Electrophysiol. 2018 Apr;29(4):609-615
pubmed: 29364546
Lancet Infect Dis. 2016 Dec;16(12):e288-e303
pubmed: 27816414
Infect Control Hosp Epidemiol. 2019 Aug;40(8):855-862
pubmed: 31159895
J Am Coll Cardiol. 2018 Dec 18;72(24):3098-3109
pubmed: 30545448
N Engl J Med. 2019 May 16;380(20):1895-1905
pubmed: 30883056
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699